Epigenic Therapeutics and NRG Therapeutics Each Secure ~$60M in Series B Rounds for Epigenetic and Neuroscience Advances

Epigenic Therapeutics closed a $60 million Series B funding round, led by Lapam Capital and joined by Qiming Venture Partners, OrbiMed, and others, to advance its lead epigenetic programs for chronic hepatitis B and hypercholesterolemia135.

The funding will support ongoing clinical trials for EPI-003 (chronic hepatitis B) and EPI-001 (hypercholesterolemia), and further development of the company’s EPIREG™ platform, which silences genes through DNA methylation and histone modification13.

NRG Therapeutics raised £50 million (approximately $67 million) in a Series B round with investors including SV Health Investors, Novartis Venture Fund, and others, with the goal of advancing its lead asset NRG5051 through clinical proof-of-concept studies in ALS and supporting a Phase 1b study in Parkinson’s disease35.

NRG5051 is designed to block disease-causing pores in mitochondria, and the company plans to begin clinical trials in ALS and Parkinson's disease in the near future35.

Both funding rounds underscore strong investor interest in gene-based and neurological treatments, with Epigenic focusing on epigenetic modulation for metabolic and infectious diseases and NRG targeting neurodegenerative disorders through mitochondrial mechanisms135.

Sources:

1. https://trial.medpath.com/news/3f0dacdb5e164432/epigenic-therapeutics-secures-60-million-series-b-to-advance-epigenetic-therapies-for-hepatitis-b-and-cholesterol

3. https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-25

5. https://techstartups.com/2025/09/08/top-startup-and-tech-funding-news-september-8-2025/